Adverum Biotechnologies News

Adverum Biotechnologies To Present LUNA 26-Week Phase 2 Interim Analysis At The ASRS Annual Scientific Meeting

Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the compan

BenzingaApr 25 16:40 ET

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NAS

BenzingaApr 23 16:31 ET

Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?

Yahoo FinanceApr 23 09:40 ET

Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?

Yahoo FinanceApr 4 09:40 ET

Analysts Are Neutral on These Healthcare Stocks: SAGE Therapeutics (SAGE), Adverum Biotechnologies (ADVM)

TipRanksMar 27 21:50 ET

Adverum Biotechnologies Files for $200M Mixed Securities Shelf

Seeking AlphaMar 21 17:40 ET

Express News | Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Moomoo 24/7Mar 21 08:55 ET

Positive Outlook for Adverum Biotechnologies With Upcoming Ixo-vec Milestones and Strong Financial Position

TipRanksMar 21 02:46 ET

Adverum Biotechnologies Reports Encouraging Clinical Progress Amidst Financial Adjustments

Yahoo FinanceMar 20 05:33 ET

Brexit Uncertainty: Navigating New Risks and Regulatory Hurdles for Adverum Biotechnologies

TipRanksMar 20 02:00 ET

Adverum Biotechnologies To Carry Out 1-for-10 Reverse Stock Split On March 21st, 2024

March 20th - $Adverum Biotechnologies(ADVM.US)$ is about to implement a 1-for-10 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from March 21st, 2024.$Adverum B

moomoo NewsMar 19 19:35 ET

Graphite Bio, SCWorx, Acurx Pharmaceuticals Among Healthcare Movers

Seeking AlphaMar 19 10:00 ET

Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

Yahoo FinanceMar 19 09:40 ET

Adverum Biotechnologies Price Target Maintained With a $4.00/Share by Chardan Capital

Adverum Biotechnologies Price Target Maintained With a $4.00/Share by Chardan Capital

Dow JonesMar 19 09:03 ET

Chardan Capital Reiterates Buy on Adverum Biotechnologies, Maintains $4 Price Target

Chardan Capital analyst Daniil Gataulin reiterates Adverum Biotechnologies with a Buy and maintains $4 price target.

Analyst UpgradesMar 19 08:54 ET

Adverum Biotechnologies Price Target Cut to $2.00/Share From $3.00 by RBC Capital

Adverum Biotechnologies Price Target Cut to $2.00/Share From $3.00 by RBC Capital

Dow JonesMar 19 08:23 ET

Adverum Biotechnologies Is Maintained at Sector Perform by RBC Capital

Adverum Biotechnologies Is Maintained at Sector Perform by RBC Capital

Dow JonesMar 19 08:23 ET

RBC Capital Maintains Sector Perform on Adverum Biotechnologies, Lowers Price Target to $2

RBC Capital analyst Luca Issi maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Sector Perform and lowers the price target from $3 to $2.

BenzingaMar 19 08:13 ET

Adverum Biotechnologies Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/19/2024 21.95% RBC Capital $3 → $2 Maintains Sector Perform 02/06/2024 143.9% Mizuho $2 → $4 Maintains

BenzingaMar 19 08:12 ET

RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk

Adverum Biotechnologies (ADVM) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $2 to $6.

MT NewswiresMar 19 07:09 ET